Posted 24th September 2018 by Kate Barlow
Thanks to advancements in human tissue sample procedures, we have been able to make major breakthroughs in cancer research. In the twenty-first century, epidemiological and clinical evidence have supported the claim that changes in metabolism can affect oncogenesis and tumour response to therapy.
It has been observed that metabolic conditions such as hyperglycemia, obesity, hyperlipidemia, and insulin resistance are directly associated with increased risk of cancer development as well as the acceleration of tumour progression. These findings indicate that statins and metformin may help decrease cancer-related deaths.
Posted 19th September 2018 by Kate Barlow
Shona Kerr, MRC Human Genetics Unit, writes:
Large-scale national cohorts and biobanks, linked to detailed genomic, phenotypic and clinical data, are currently being created and developed through investment from a large number of governments worldwide. These data-rich resources are exemplified by the 500,000 research volunteers in the UK Biobank, a cohort established primarily to investigate the genetic and lifestyle determinants of middle and later life diseases. Now it is accessible by all health researchers worldwide and the UK Biobank is supporting an unprecedented range of novel insights into the biology of disease, from varicose veins to lifespan.
Posted 17th September 2018 by Kieran Chambers
Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.
Posted 14th September 2018 by Kate Barlow
As diet and the microbiome are closely entwined, the first step in understanding a healthy infant gut microbiome is to understand a healthy infant diet. Fortunately, a healthy infant diet is at least superficially simple to define, exclusive breastfeeding for the first six months is the best nutrition for infants according to the World Health Organisation. A common alternative to human breast milk for infants is formula and the microbiomes of breastfed and formula fed infants are known to differ.
Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Kieran Chambers
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Posted 10th September 2018 by Jane Williams
At the recent Digital Pathology and AI Congress, Rebecca Calder and Daniel Stevens presented their research in the poster entitled: Preliminary Studies in the Use of the Foldscope Paper Microscope for Diagnostic Analysis of Crystals in Urine: Issues in the Analysis of Liquid Samples and Potential Applications in Low Budget/Low Tech Regions of the World. You can view the poster here.
Dr. Zev Leifer, who oversaw the project, describes the rationale.
Posted 7th September 2018 by Kate Barlow
Antibiotic use can disrupt your body’s protective microbial barrier and open the door to pathogens and illness. Our research focuses on developing next-generation probiotics that would selectively prevent infection by the bacterium Clostridium difficile, a gastrointestinal pathogen that produces toxins resulting in watery diarrhoea and in severe cases, pseudomembrane colitis, toxemia, sepsis and death.
Posted 5th September 2018 by Kieran Chambers
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.